Notably, when all other conditions were held constant at the reference values (53‐year‐old patient weighing 75 kg with no GvHD in the liver, skin, or intestine, an albumin value of 40 g/L, and a lymphocyte count of 0.1 K/μL), vedolizumab AUCss increased by about 20% for subjects with low body weight (10th percentile: 51 kg) or high albumin (90th percentile: 46 g/L), and AUCss decreased by about 25% for subjects with high body weight or low albumin. Here, ALB is linked to graft versus host disease.